TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06690216

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT （[18F]AlF-NOTA-PCP2）
Description: This intervention involves the use of \[18F\]AlF-NOTA-PCP2, a radiopharmaceutical agent specifically designed for PET/CT imaging. Patients will receive an intravenous injection of \[18F\]AlF-NOTA-PCP2, followed by whole-body PET/CT scanning one hour later. The primary purpose of this intervention is to assess PD-L1 expression in malignant tumors, including glioblastoma, head and neck squamous cell carcinoma, non-small cell lung cancer, and esophageal cancer, before the initiation of treatment. This imaging technique offers a non-invasive, repeatable, and comprehensive method to monitor PD-L1 status, in contrast to traditional tissue biopsy, which is invasive and limited to a single time point.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]AlF-NOTA-PCP2 PET/CT Imaging for PD-L1 Expression in Malignant Tumors
Description: This intervention involves the use of \[18F\]AlF-NOTA-PCP2, a radiopharmaceutical agent specifically designed for PET/CT imaging. Patients will receive an intravenous injection of \[18F\]AlF-NOTA-PCP2, followed by whole-body PET/CT scanning one hour later. The primary purpose of this intervention is to assess PD-L1 expression in malignant tumors, including glioblastoma, head and neck squamous cell carcinoma, non-small cell lung cancer, and esophageal cancer, before the initiation of treatment. This imaging technique offers a non-invasive, repeatable, and comprehensive method to monitor PD-L1 status, in contrast to traditional tissue biopsy, which is invasive and limited to a single time point.
Study: NCT06687356

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery with Intraoperative Optical Coherence Tomography application
Description: Surgery with the application of intraoperative optical coherence tomography technique. Intraoperative optical coherence tomography technique can provide intraocular images and show changes in intraocular structures, assisting in analyzing the correlation between preoperative, intraoperative anterior segment structural changes and postoperative surgical effects in patients with lens diseases.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional surgery
Description: Conventional lens surgery, without the application of intraoperative optical coherence tomography technique.
Study: NCT06686771

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Please refer to the current NCCN NSCLC guidelines for possible treatment options

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Second-line standard of care therapy
Description: Please refer to the current NCCN NSCLC guidelines for possible treatment options.
Study: NCT06690853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Coordinative training
Description: The warm-up protocols of the Experimental Group included four types of upper and lower limb coordination exercises using different-sized balls, with intensity increasing week by week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional training (control group)
Description: The Control Group warm-up protocol only involved joint mobility exercises and muscle activation, as used in their regular training activities.
Study: NCT06231836

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal cannula
Description: O2 is administered by nasal cannula at 6L/min
Study: NCT06690580

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational interviewing based on the knowledge motivation behavior skills model
Description: Breastfeeding education that includes motivational interviews based on the knowledge motivation behavior skills model
Study: NCT06688565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hativ® electrocardiogram monitoring
Description: Using Hativ®, a currently commercially available class II medical device, ECGs are measured every day at home and before and after dialysis
Study: NCT06686407

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open lumbar decompression ± fusion
Description: Open lumbar decompression by laminectomy and transpedicular screw fixation using screws and rods ± interbody cage device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive lumbar foraminal decompression using unilateral biportal endoscopy device
Description: A new endoscopic technique that uses a Unilater Biportal Endoscopy for lumbar foraminal decompression
Study: NCT06164730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VERVE-102
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VERVE-102
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VERVE-102
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VERVE-102
Description: Intravenous (IV) infusion
Study: NCT06117241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMAGINE HEALTHY
Description: An anti-inflammatory nutrition program including cooking classes, physical activity, and stress reduction.
Study: NCT05156476

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Genicular nerve block-iPACK group
Description: Group 1: Genicular nerve block-iPACK group (performed by anaesthesiologist) Method: Ultrasound and nerve stimulation guided injection Drug: a total of 30 ml of ropivacaine 0,5% (150 mg) will be used

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral triangle block-iPACK group
Description: Group 2: Femoral triangle block-iPACK group (performed by anaesthesiologist) Method: Ultrasound and nerve stimulation guided injection Drug: a total of 30 ml of ropivacaine 0,5% (150 mg) will be used

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration analgesia
Description: Group 3: LIA (performed by surgeon) Method: Blind injection Drug: a total of 200ml of 0.2% ropivacaine will be used (400mg). Of this, 150ml of ropivacaine 0.2% will be mixed with 1mg of adrenaline.
Study: NCT04896021

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiovascular disease risk assessment
Description: Intervention in which the addition of guideline-recommended absolute cardiovascular disease risk assessment is embedded into point-of-care blood collection services for cholesterol measurement and results (including risk score) are reported to referring doctors.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Usual care assessment
Description: Usual care in which blood cholesterol results are reported to referring doctors
Study: NCT05087849

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nonavalent human papillomavirus vaccine
Description: Intralesional injection of nonavalent human papillomavirus vaccine (Gardasil 9) at 0 and 4 weeks
Study: NCT04998682

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary Dissection
Description: A surgical procedure that opens the armpit (axilla) to identify, examine, or remove lymph nodes. Axillary dissection will be performed during SoC breast cancer surgery.
Study: NCT05897970

Intervention type: DIAGNOSTIC_TEST
Intervention: Return-to-sport (RTS) follow-up
Description: All sports patients who had a muscle evaluation at 3-4 months after ACLR since January 2017
Study: NCT06693141

Intervention type: OTHER
Intervention: ESP block
Description: ESP block was applied to the patients.

Intervention type: OTHER
Intervention: ITM
Description: ITM was applied to the patients.
Study: NCT06695533

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes self management workbook
Description: The diabetes self-management workbook section used in this pilot study will focus on diet management, specifically carbohydrates, following ADA guidelines. It will include exercises based on the ADA diabetes plate method, aimed at helping subjects understand meal planning, food categories, portion sizes, goal setting, and the impact of foods on blood glucose levels. Activities will include word searches, crosswords, and goal-setting exercises. Subjects will begin the first section during a clinic visit. They can complete the workbook at home over three months, with input from subjects and Certified Diabetes Care and Education Specialists to refine the content.
Study: NCT06687096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A recipe booklet
Description: A recipe resource with visuals in line with the low-residue diet recommendations given to patients before colonoscopy, including cooking instructions for the meals in the diet list.

Intervention type: OTHER
Group type: OTHER
Intervention: standart diet list
Description: patients prepared with a routine colonoscopy preparation scheme
Study: NCT06689410

Intervention type: OTHER
Group type: OTHER
Intervention: blood or saliva sample
Description: Collection of blood or saliva
Study: NCT06630897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Messages
Description: small amounts of digital support will be in the form of text messages
Study: NCT05530291

Intervention type: OTHER
Intervention: Non-interventional
Description: Epidemiology of anemia associated with chronic kidney disease, rather than to evaluate specific drugs

Intervention type: OTHER
Intervention: Non-interventional
Description: Epidemiology of anemia associated with chronic kidney disease, rather than to evaluate specific drugs
Study: NCT06632054

Intervention type: BEHAVIORAL
Intervention: Text Message Reminders
Description: Text message reminders (instead of usual care - phone call reminders) to complete FIT for colon cancer screening.
Study: NCT06129123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Live Free From E-cigarettes
Description: This is a 30-minute online educational program that focuses on providing information about e-cigarette and smoking social norms, harms of e-cigarettes and cigarettes, and ways to quit or reduce using e-cigarettes.
Study: NCT06035211

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3D model pré-operative education
Description: Before surgery, during a preoperative therapeutic education consultation, 3D models will be presented to the patients according to the allocated study group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3D model pré-operative education
Description: Before surgery, during a preoperative therapeutic education consultation, 3D models will be presented to the patients according to the allocated study group
Study: NCT05545228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Link work intervention
Description: Intervention from a link worker to support participants to access dental services.
Study: NCT05768087

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Escalated proton therapy
Description: According to allocated dose level: level 1-8, 69-90 Gy in 30 fractions of 2.3-3.0 Gy, to a subvolume of the radiation target
Study: NCT06690866

Intervention type: BEHAVIORAL
Intervention: Stress
Description: Montreal Imaging Stress Task is a stress paradigm in the scanner to examine neuronal correlates of acute psychosocial stress.

Intervention type: BEHAVIORAL
Intervention: Stress
Description: Montreal Imaging Stress Task is a stress paradigm in the scanner to examine neuronal correlates of acute psychosocial stress.
Study: NCT05575557

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right heart catheterization
Description: All groups were detected with SW catheter by the internal jugular vein before the procedure. After the measurement, the catheter was indwelled, and the pacemaker implantation procedure was started. After ventricular pacing for 5 minutes, the SW catheter measurement was performed again. After the measurement, the SW catheter was withdrawn.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right heart catheterization
Description: All groups were detected with SW catheter by the internal jugular vein before the procedure. After the measurement, the catheter was indwelled, and the pacemaker implantation procedure was started. After ventricular pacing for 5 minutes, the SW catheter measurement was performed again. After the measurement, the SW catheter was withdrawn.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right heart catheterization
Description: All groups were detected with SW catheter by the internal jugular vein before the procedure. After the measurement, the catheter was indwelled, and the pacemaker implantation procedure was started. After ventricular pacing for 5 minutes, the SW catheter measurement was performed again. After the measurement, the SW catheter was withdrawn.
Study: NCT05307276

Intervention type: OTHER
Group type: OTHER
Intervention: Heliox
Description: Participants will then complete 1 FAM (#V3) to Neuromuscular Function Assessment (PRE-POST), Pre- and Post- Exercise Ventilatory Function Assessment, and a Constant Load Ergocycle Test to Tolerance Limit (intensity fixed at 90% of the maximum aerobic power, PMA). The following two experimental visits (#V4 and #V5) will replicate the tests described in #V3. However, during the constant load exercise, participants will breathe either ambient air or heliox (a mixture in which the nitrogen in the air is replaced by the inert gas helium) in a random order. During a final Experiential Visit (#V6), participants will replicate the Medical Gas Administration visit but the exercise will be interrupted when a similar amount of time/work as the ambient air condition is achieved.

Intervention type: OTHER
Group type: OTHER
Intervention: Air
Description: Following the selection visit (#V0) to verify the inclusion and non-inclusion criteria, participants will make 2 visits (#V1 and #V2) including in particular a Respiratory Functional Exploration (EFR) and a triangular VO2 MAX estimation test in Ambient Air or Heliox conditions (depending on randomization).
Study: NCT04945096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Decitabine (20mg/m2 intravenously from day -10 to day -8 of conditional regimen)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Description: Acetylcysteine: 1.2g twice a day, oral administration, from day -10 to day 365 after HSCT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semustine
Description: Semustine: 250 mg/m2/day on day -9.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semustine
Description: Semustine: 250 mg/m2/day on day -9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine: 2 g/m2 every 12 hours on day -8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Cytarabine: 2 g/m2 every 12 hours on day -8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan: 3.2mg/kg/day on day -7 to -5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: Busulfan: 3.2mg/kg/day on day -7 to -5.
Study: NCT04976036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: 150 mg oral nintedanib soft caps, once a day for 2 weeks and twice a day for 10 weeks (12 hours interval)
Study: NCT04945096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide: 1.8g/m2/day on day -4 to -3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide: 1.8g/m2/day on day -4 to -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Description: Cyclosporin A: 3mg/kg/d from day -8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin A
Description: Cyclosporin A: 3mg/kg/d from day -8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin
Description: Anti-thymocyte globulin (2mg/kg/d on day -5 to day -2) will be added for transplants with unrelated donor or HLA mismatched donor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-thymocyte globulin
Description: Anti-thymocyte globulin (2mg/kg/d on day -5 to day -2) will be added for transplants with unrelated donor or HLA mismatched donor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate
Description: Mycophenolate (500mg, oral, twice a day from day -8) will be added for transplants with unrelated donor or HLA mismatched donor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate
Description: Mycophenolate (500mg, oral, twice a day from day -8) will be added for transplants with unrelated donor or HLA mismatched donor.
Study: NCT05721755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study: NCT06175741

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: erector spinae plane block
Description: The ultrasound (US)-guided ESP block will be provided while the patient be in a seated position according to surgical site (right or left). Using high-frequency linear US transducer , the probe is placed in the longitudinal orientation lateral to thoracic third and six spinous processes ,then the trapezius muscle ,rhomboids major muscle and erector spinae muscle are identified and we will inject 20ml of 0.25% bupivacaine into interfacial plane below erector spinae muscle in one level (between T3and T6) ,alone in 1st group,with 3 mg morphine in 2nd group and 5 mg morphine in 3rd group

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae plane block
Description: The ultrasound (US)-guided ESP block will be provided while the patient be in a seated position according to surgical site (right or left). Using high-frequency linear US transducer , the probe is placed in the longitudinal orientation lateral to thoracic third and six spinous processes ,then the trapezius muscle ,rhomboids major muscle and erector spinae muscle are identified and we will inject 20ml of 0.25% bupivacaine into interfacial plane below erector spinae muscle in one level (between T3and T6) ,alone in 1st group,with 3 mg morphine in 2nd group and 5 mg morphine in 3rd group

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae plane block
Description: The ultrasound (US)-guided ESP block will be provided while the patient be in a seated position according to surgical site (right or left). Using high-frequency linear US transducer , the probe is placed in the longitudinal orientation lateral to thoracic third and six spinous processes ,then the trapezius muscle ,rhomboids major muscle and erector spinae muscle are identified and we will inject 20ml of 0.25% bupivacaine into interfacial plane below erector spinae muscle in one level (between T3and T6) ,alone in 1st group,with 3 mg morphine in 2nd group and 5 mg morphine in 3rd group
Study: NCT06689124

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized fentanyl
Description: After the enrollment process, the main research assistant will take a brown envelope containing the randomization and hand it to the principal investigator in numerical order. The principal investigator will then open the envelope to determine the group assignment for the patient, revealing which fentanyl nebulization dosage group (2 mcg/kg, 3 mcg/kg and 4 mcg/kg) the patient will be placed in. In this study, participants will be divided into three groups as previously described. We evaluate pain score at 0, 15, 30, 45, 60, 75, 90, 105 and 120 minutes after receiving nebulized fentanyl by a train research assistance who is blind from the treatment dosage.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized fentanyl
Description: After the enrollment process, the main research assistant will take a brown envelope containing the randomization and hand it to the principal investigator in numerical order. The principal investigator will then open the envelope to determine the group assignment for the patient, revealing which fentanyl nebulization dosage group (2 mcg/kg, 3 mcg/kg and 4 mcg/kg) the patient will be placed in. In this study, participants will be divided into three groups as previously described. We evaluate pain score at 0, 15, 30, 45, 60, 75, 90, 105 and 120 minutes after receiving nebulized fentanyl by a train research assistance who is blind from the treatment dosage.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized fentanyl
Description: After the enrollment process, the main research assistant will take a brown envelope containing the randomization and hand it to the principal investigator in numerical order. The principal investigator will then open the envelope to determine the group assignment for the patient, revealing which fentanyl nebulization dosage group (2 mcg/kg, 3 mcg/kg and 4 mcg/kg) the patient will be placed in. In this study, participants will be divided into three groups as previously described. We evaluate pain score at 0, 15, 30, 45, 60, 75, 90, 105 and 120 minutes after receiving nebulized fentanyl by a train research assistance who is blind from the treatment dosage.
Study: NCT06688188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-JH12
Description: The dose will be 148-222 MBq given intravenously.
Study: NCT06691477

Intervention type: OTHER
Intervention: No Interventions
Description: No intervention required. Subjects accepted regular medical treatment

Intervention type: OTHER
Intervention: No Interventions
Description: No intervention required. Subjects accepted regular medical treatment
Study: NCT06690346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systematic oral health education
Description: Provide systematic oral health education to patients in experimental group, including oral hygiene instruction and dietary instruction

Intervention type: OTHER
Group type: OTHER
Intervention: Routine oral health education
Description: Provide routine oral health education to patients in control group, including routine oral self-care instruction
Study: NCT06686329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control (CON)
Description: Standardized meal with insulin administered 15 minutes before eating

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Missed Dose (MISS)
Description: Standardized meal with insulin administered post-prandially when alerted to rapidly rising glucose (increase of 0.2 mmol/L/min) or hyperglycemia (\> 10.0 mmol/L) by CGM

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Missed Dose + 15min walk (MISS+EX)
Description: Standardized meal with insulin administered post-prandially when alerted to rapidly rising glucose (increase of 0.2 mmol/L/min) or hyperglycemia (\> 10.0 mmol/L) by CGM with a 15-minute walk performed immediately after insulin administration